EPS for Biopharmx Corp (BPMX) Expected At $-0.06

November 20, 2017 - By Henry Gaston

 EPS for Biopharmx Corp (BPMX) Expected At $ 0.06

Analysts expect Biopharmx Corp (NYSEAMERICAN:BPMX) to report $-0.06 EPS on December, 12.They anticipate $0.07 EPS change or 53.85 % from last quarter’s $-0.13 EPS. After having $-0.06 EPS previously, Biopharmx Corp’s analysts see 0.00 % EPS growth. The stock decreased 2.63% or $0.005 on November 20, reaching $0.185. About 462,144 shares traded. Biopharmx Corp (NYSEAMERICAN:BPMX) has declined 5.75% since November 21, 2016 and is downtrending. It has underperformed by 22.45% the S&P500.

BioPharmX Corporation is a specialty pharmaceutical company. The company has market cap of $14.74 million. The Firm is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter products that address markets in women’s health and dermatology. It currently has negative earnings. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.